Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 1
2018 1
2019 1
2020 3
2021 7
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Schistosoma mansoni-specific immune responses and allergy in Uganda.
Nkurunungi G, Kabagenyi J, Nampijja M, Sanya RE, Walusimbi B, Nassuuna J, Webb EL, Elliott AM; LaVIISWA study team. Nkurunungi G, et al. Parasite Immunol. 2018 Jan;40(1):e12506. doi: 10.1111/pim.12506. Epub 2017 Dec 15. Parasite Immunol. 2018. PMID: 29171863 Free PMC article.
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Zirimenya L, Nkurunungi G, Nassuuna J, Natukunda A, Mutebe A, Oduru G, Kabami G, Akurut H, Onen C, Namutebi M, Serubanja J, Nakazibwe E, Akello F, Tumusiime J, Sewankambo M, Kiwanuka S, Kiwudhu F, Kizindo R, Kizza M, Wajja A, Cose S, Muwanga M, Webb E, Elliott AM; POPVAC trial team. Zirimenya L, et al. BMJ Open. 2021 Feb 16;11(2):e040430. doi: 10.1136/bmjopen-2020-040430. BMJ Open. 2021. PMID: 33593770 Free PMC article.
Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Nkurunungi G, Zirimenya L, Nassuuna J, Natukunda A, Kabuubi PN, Niwagaba E, Oduru G, Kabami G, Amongin R, Mutebe A, Namutebi M, Zziwa C, Amongi S, Ninsiima C, Onen C, Akello F, Sewankambo M, Kiwanuka S, Kizindo R, Kaweesa J, Cose S, Webb E, Elliott AM; POPVAC trial team; POPVAC trial team principal investigator. Nkurunungi G, et al. BMJ Open. 2021 Feb 16;11(2):e040426. doi: 10.1136/bmjopen-2020-040426. BMJ Open. 2021. PMID: 33593768 Free PMC article.
Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics.
Nkurunungi G, Zirimenya L, Natukunda A, Nassuuna J, Oduru G, Ninsiima C, Zziwa C, Akello F, Kizindo R, Akello M, Kaleebu P, Wajja A, Luzze H, Cose S, Webb E, Elliott AM; POPVAC trial team. Nkurunungi G, et al. BMJ Open. 2021 Feb 16;11(2):e040425. doi: 10.1136/bmjopen-2020-040425. BMJ Open. 2021. PMID: 33593767 Free PMC article.
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Natukunda A, Nkurunungi G, Zirimenya L, Nassuuna J, Oduru G, Amongin R, Kabuubi PN, Mutebe A, Onen C, Amongi S, Nakazibwe E, Akello F, Kiwanuka S, Kiwudhu F, Sewankambo M, Nsubuga D, Kizindo R, Staedke SG, Cose S, Webb E, Elliott AM; POPVAC trial team. Natukunda A, et al. BMJ Open. 2021 Feb 16;11(2):e040427. doi: 10.1136/bmjopen-2020-040427. BMJ Open. 2021. PMID: 33593769 Free PMC article.
The Impact of Intensive Versus Standard Anthelminthic Treatment on Allergy-related Outcomes, Helminth Infection Intensity, and Helminth-related Morbidity in Lake Victoria Fishing Communities, Uganda: Results From the LaVIISWA Cluster-randomized Trial.
Sanya RE, Nkurunungi G, Hoek Spaans R, Nampijja M, O'Hara G, Kizindo R, Oduru G, Kabuubi Nakawungu P, Niwagaba E, Abayo E, Kabagenyi J, Zziwa C, Tumusiime J, Nakazibwe E, Kaweesa J, Muwonge Kakooza F, Akello M, Lubyayi L, Verweij J, Nash S, van Ree R, Mpairwe H, Tukahebwa E, Webb EL, Elliott AM; LaVIISWA Trial Team. Sanya RE, et al. Clin Infect Dis. 2019 May 2;68(10):1665-1674. doi: 10.1093/cid/ciy761. Clin Infect Dis. 2019. PMID: 30202872 Free PMC article. Clinical Trial.
14 results